Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Julia F. Kuder"'
Autor:
KyungAh Im, Robert F. Storey, Marc P. Bonaca, Christian W. Hamm, Andrzej Budaj, Brian A. Bergmark, Róbert Gábor Kiss, Per Johanson, Julia F Kuder, Frans Van de Werf, Jindřich Špinar, Deepak L. Bhatt, Giulia Magnani, Eugene Braunwald, Ton Oude Ophuis, Marc S. Sabatine, Gilles Montalescot, Yared Gurmu, P. Gabriel Steg
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 17 (2021)
Journal of the American Heart Association
Journal of the American Heart Association, Wiley-Blackwell, 2021, 10 (17), ⟨10.1161/JAHA.120.020446⟩
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 17 (2021)
Journal of the American Heart Association
Journal of the American Heart Association, Wiley-Blackwell, 2021, 10 (17), ⟨10.1161/JAHA.120.020446⟩
Background Coronary stent type and risk of stent thrombosis remain important factors affecting recommended duration of dual antiplatelet therapy. We investigated the efficacy and safety of long‐term ticagrelor in patients with prior coronary stenti
Autor:
Giuseppe Boriani, Minggao Shi, Elliott M. Antman, Eugene Braunwald, Julia F Kuder, Christian T. Ruff, Robert P. Giugliano, Hans Lanz
Background The effects of anticoagulants at extremes of body weight (BW) are not well described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics and clinical outcomes in patients randomized to warfarin, higher dose edoxaban
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::058591ee3f771b93c0121f8baae0e732
https://hdl.handle.net/11380/1227041
https://hdl.handle.net/11380/1227041
Autor:
E Braunwald, Julia F Kuder, Christian T. Ruff, G Boriani, Robert P. Giugliano, Minggao Shi, Elliot M Antman, H Lanz
Publikováno v:
European Heart Journal. 40
Background The impact on outcomes of oral anticoagulants in pts at extremes of body weight have not been well-characterized. Aim To analyse the outcomes of pts with atrial fibrillation (AF) enrolled in ENGAGE AF-TMI 48 randomized to warfarin (W) targ
Autor:
Rangasamy Muthusamy, Marc S. Sabatine, Francesco Franchi, Marc Cohen, Marc P. Bonaca, Ramzi A. Ajjan, Julia F Kuder, Robert F. Storey, Philippe Gabriel Steg, Mark R Thomas, Heather M Judge, Dominick J. Angiolillo, Fabiana Rollini, Deepak L. Bhatt, Arif J. Ahsan
Publikováno v:
Thrombosis and Haemostasis. 117:940-947
SummaryDiabetes increases cardiovascular risk and reduces pharmacodynamic response to some oral antiplatelet drugs. This study aimed to determine whether ticagrelor 60 mg twice daily (bid) provided potent and consistent platelet inhibition in patient
Autor:
Petr Jarolim, Marc A. Pfeffer, Julia F Kuder, Brian A. Bergmark, David A. Morrow, Marc S. Sabatine, Scott D. Solomon, Eugene Braunwald, Jacob A. Udell
AIMS Klotho, an essential co-receptor for fibroblast growth factor (FGF)-23, has potentially beneficial inhibitory effects on the renin-angiotensin system. Limited data exist on the prognostic value of Klotho and FGF-23 levels in combination or their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45d872158b157a55c46b22e93dc70514
https://europepmc.org/articles/PMC6458082/
https://europepmc.org/articles/PMC6458082/
Autor:
Stephen D. Wiviott, Julia F Kuder, Eva C. Jensen, Andrzej Budaj, Giulia Magnani, Alexander Parkhomenko, Eugene Braunwald, Robert F. Storey, Marc S. Sabatine, Jose Lopez-Sendon, Marc P. Bonaca, Per Johanson, Assen Goudev, Frans Van de Werf, Jose C. Nicolau, KyungAh Im, Marc Cohen, Deepak L. Bhatt, P. Gabriel Steg, Ramón Corbalán, Christian W. Hamm, Mikael Dellborg, David A. Morrow, Rafael Diaz
Publikováno v:
Journal of the American Heart Association. 7
Background Ticagrelor reduced cardiovascular death, myocardial infarction (MI), or stroke in patients with prior MI in PEGASUS‐TIMI 54 (Prevention of Cardiovascular Events [eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patie
Autor:
Philippe Gabriel Steg, Marc Cohen, Deepak L. Bhatt, Francesco Franchi, Dominick J. Angiolillo, Heather M Judge, Marc P. Bonaca, Marc S. Sabatine, Rangasamy Muthusamy, Fabiana Rollini, Robert F. Storey, Eugene Braunwald, Arif J. Ahsan, Mark R Thomas, Julia F Kuder
Publikováno v:
Journal of the American College of Cardiology. 67:1145-1154
Background The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis In Myocardial Infarction 54) trial studied 2 doses of ticagrelor, 9
Autor:
Michele Mercuri, Elliott M. Antman, Eugene Braunwald, Howard Rutman, Minggao Shi, Hans Lanz, Julia F Kuder, Christian T. Ruff, Robert P. Giugliano, Giuseppe Boriani
Publikováno v:
European heart journal. 40(19)
Aims To investigate the relationship between body mass index (BMI) and outcomes in patients with atrial fibrillation (AF). Methods and results In the ENGAGE AF-TIMI 48 trial, patients with AF were randomized to warfarin (international normalized rati
Autor:
Basil S. Lewis, Gaetano M. De Ferrari, Kurt Huber, Terje R. Pedersen, Robert P. Giugliano, Anthony C Keech, Peter S. Sever, Narimon Honarpour, Jorge Ferreira, Stephen D. Wiviott, Christopher E. Kurtz, Julia F Kuder, Sabina A. Murphy, Marc S. Sabatine
Background: The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab significantly reduced ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2055f29b42e24c07d54f11013f00c3
http://hdl.handle.net/2318/1732420
http://hdl.handle.net/2318/1732420
Autor:
Karen Brown, Sabina A. Murphy, Petr Jarolim, David A. Morrow, Julia F Kuder, Naveen Deenadayalu, Joshua Betcher, Elliott M. Antman, Christian T. Ruff, Robert P. Giugliano, Minggao Shi, Michele Mercuri, Eugene Braunwald, Indravadan Patel
Publikováno v:
The Lancet. 385:2288-2295
Summary Background New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vitamin K antagonists. A concern h